Viberzi
Loading...Viberzi Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no side effect or adverse reaction information available for this drug.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
There is current no usage information for this drug.
History
There is currently no drug history available for this drug.
Other Information
There is currently no other information available for this drug.
Sources
Viberzi Manufacturers
-
Actavis Pharma, Inc
![Viberzi (Eluxadoline) Tablet, Film Coated [Actavis Pharma, Inc]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Viberzi | Actavis Pharma, Inc
The recommended dosage of VIBERZI is 100 mg taken orally twice daily with food.
The recommended dosage of VIBERZI is 75 mg taken orally twice daily with food in patients who:
do not have a gallbladder [see Warnings and Precautions (5.1), Adverse Reactions (6.1)]. are unable to tolerate the 100 mg dose of VIBERZI [see Adverse Reactions (6.1)]. are receiving concomitant OATP1B1 inhibitors [see Drug Interactions (7)]. have mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment [see Use in Specific Population (8.6), Clinical Pharmacology (12.3)].Discontinue VIBERZI in patients who develop severe constipation for more than 4 days.
Instruct patients if they miss a dose, take the next dose at the regular time and not to take 2 doses at the same time to make up for a missed dose.
Login To Your Free Account